Return to homepagePandemic Pact

Comparing Safety and Effectiveness of Medicines Patients Take for Many Years to Treat Multiple Sclerosis (MS) -- The COMBAT-MS Study

  • Funded by Patient-Centered Outcomes Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $475,400

  • Funder

    Patient-Centered Outcomes Research Institute

  • Principal Investigator

    MD. Fredrik Piehl

  • Research Location

    Sweden

  • Lead Research Institution

    Karolinska Institutet

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidity

  • Occupations of Interest

    Unspecified

Abstract

Given the immunomodulatory nature of disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) and the infection risk associated with some of these agents, patients with MS and the clinicians who treat them have many questions about the relative safety of various DMTs in the time of COVID-19 and the effects of these drugs on individuals who do become infected with SARS-CoV2. The enhancements to this study aim assess the risk of adverse outcomes associated with COVID-19 in MS patients treated with different DMTs and assess the serological response to SARS-CoV2 infection, severity of infection, and clinical outcomes pre- and post-COVID-19.